Biomarkers in Recurrent Grade III Glioma Patients Treated with Bevacizumab and Irinotecan

被引：7
作者：
Toft, Anders [1 ,2 ]
Urup, Thomas [1 ,3 ]
Christensen, Ib Jarle
Michaelsen, Signe Regner [1 ]
Lukram, Babloo [4 ]
Grunnet, Kirsten [1 ,2 ]
Kosteljanetz, Michael [5 ]
Larsen, Vibeke Andree [6 ]
Lassen, Ulrik [1 ,2 ,7 ]
Broholm, Helle
Poulsen, Hans Skovgaard [1 ,2 ,4 ]
机构：
[1] Rigshosp, Finsen Ctr, Dept Radiat Biol, Blegdamsvej 9, Copenhagen, Denmark
[2] Rigshosp, Finsen Ctr, Dept Oncol, Copenhagen, Denmark
[3] Hvidovre Univ Hosp, Dept Surg Gastroenterol, Hvidovre, Denmark
[4] Rigshosp, Ctr Diagnost Invest, Dept Pathol, Copenhagen, Denmark
[5] Rigshosp, Neurosci Ctr, Dept Neurosurg, Copenhagen, Denmark
[6] Rigshosp, Ctr Diagnost Invest, Dept Radiol, Copenhagen, Denmark
[7] Rigshosp, Finsen Ctr, Phase Unit I, Copenhagen, Denmark
来源：
CANCER INVESTIGATION | 2018年 / 36卷 / 02期
关键词：
Cancer biomarkers; Glioma; Bevacizumab; Recurrent; Prognosis and response predictions; DIAGNOSED ANAPLASTIC OLIGODENDROGLIOMA; CENTRAL-NERVOUS-SYSTEM; PROGNOSTIC MODELS; PLUS IRINOTECAN; PRIMARY BRAIN; TRIAL; TUMORS; CLASSIFICATION; CHEMOTHERAPY; ORGANIZATION;
D O I：
10.1080/07357907.2018.1430818
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Predictive biomarkers and prognostic models are required to identify recurrent grade III glioma patients who benefit from existing treatment. In this study of 62 recurrent grade III glioma patients, a range of clinical and paraclinical factors are tested for association with progression-free survival, overall survival, and response to bevacizumab and irinotecan therapy. Significant factors from univariate screening are included in multivariate analysis. Biomarkers previously advanced as predictive or prognostic in the first-line setting did not affect outcome in this patient cohort. Based on the optimized model for overall survival, comprising performance status and p53 expression, a prognostic index is established.
引用
收藏
页码：165 / 174
页数：10
相关论文
共 41 条
[1]   Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402 [J].
Cairncross, Gregory ;
Wang, Meihua ;
Shaw, Edward ;
Jenkins, Robert ;
Brachman, David ;
Buckner, Jan ;
Fink, Karen ;
Souhami, Luis ;
Laperriere, Normand ;
Curran, Walter ;
Mehta, Minesh .
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (03) :337-343
[2]   Benefit From Procarbazine, Lomustine, and Vincristine in Oligodendroglial Tumors Is Associated With Mutation of IDH [J].
Cairncross, J. Gregory ;
Wang, Meihua ;
Jenkins, Robert B. ;
Shaw, Edward G. ;
Giannini, Caterina ;
Brachman, David G. ;
Buckner, Jan C. ;
Fink, Karen L. ;
Souhami, Luis ;
Laperriere, Normand J. ;
Huse, Jason T. ;
Mehta, Minesh P. ;
Curran, Walter J., Jr. .
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (08) :783-+
[3]   Salvage chemotherapy with bevacizumab for recurrent alkylator-refractory anaplastic astrocytoma [J].
Chamberlain, Marc C. ;
Johnston, Sandra .
JOURNAL OF NEURO-ONCOLOGY, 2009, 91 (03) :359-367
[4]   Bevacizumab for Recurrent Alkylator-Refractory Anaplastic Oligodendroglioma [J].
Chamberlain, Marc C. ;
Johnston, Sandra .
CANCER, 2009, 115 (08) :1734-1743
[5]   Recurrent high-grade glioma treated with bevacizumab: prognostic value of MGMT methylation, EGFR status and pretreatment MRI in determining response and survival [J].
Chen, Christina ;
Huang, Raymond ;
MacLean, Ainsley ;
Muzikansky, Alona ;
Mukundan, Srinivasan ;
Wen, Patrick Y. ;
Norden, Andrew D. .
JOURNAL OF NEURO-ONCOLOGY, 2013, 115 (02) :267-276
[6]   Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas [J].
Desjardins, Annick ;
Reardon, David A. ;
Herndon, James E., II ;
Marcello, Jennifer ;
Quinn, JenniferA. ;
Rich, Jeremy N. ;
Sathornsumetee, Sith ;
Gururangan, Sriclharan ;
Sampson, John ;
Bailey, Leighann ;
Bigner, Darell D. ;
Friedman, Allan H. ;
Friedman, Henry S. ;
Vredenburgh, James J. .
CLINICAL CANCER RESEARCH, 2008, 14 (21) :7068-7073
[7]   Patient outcome in the Belgian medical need program on bevacizumab for recurrent glioblastoma [J].
Duerinck, Johnny ;
Clement, Paul M. ;
Bouttens, Frank ;
Andre, Chantal ;
Neyns, Bart ;
Staelens, Yves ;
Van Fraeyenhove, Frank ;
Baurain, Jean-Francois ;
Luce, Sylvie ;
D'hondt, Lionel ;
Joosens, Eric ;
Specenier, Pol ;
Verschaeve, Vincent ;
Filleul, Bertrand ;
Vroman, Philippe ;
Stragier, Barbara ;
Rogiers, Anne .
JOURNAL OF NEUROLOGY, 2015, 262 (03) :742-751
[8]   Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma [J].
Friedman, Henry S. ;
Prados, Michael D. ;
Wen, Patrick Y. ;
Mikkelsen, Tom ;
Schiff, David ;
Abrey, Lauren E. ;
Yung, W. K. Alfred ;
Paleologos, Nina ;
Nicholas, Martin K. ;
Jensen, Randy ;
Vredenburgh, James ;
Huang, Jane ;
Zheng, Maoxia ;
Cloughesy, Timothy .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (28) :4733-4740
[9]   Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer [J].
Fuchs, CS ;
Moore, MR ;
Harker, G ;
Villa, L ;
Rinaldi, D ;
Hecht, JR .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (05) :807-814
[10]   Bevacizumab plus irinotecan in recurrent malignant glioma shows high overall survival in a multicenter retrospective pooled series of the Spanish Neuro-Oncology Research Group (GEINO) [J].
Gila, Miguel J. ;
de las Penas, Ramon ;
Reynes, Gaspar ;
Balana, Carme ;
Perez-Segura, Pedro ;
Garcia-Velasco, Adelaida ;
Mesia, Carlos ;
Gallego, Oscar ;
Fernandez-Chacon, Concepcion ;
Martinez-Garcia, Maria ;
Herrerok, Ana ;
Andres, Raquel ;
Benavides, Manuel ;
Quintanar, Teresa ;
Perez-Martin, Xavier .
ANTI-CANCER DRUGS, 2012, 23 (06) :659-665
12345